Bhavin Patel

How do you see this drug positioned relative to other newer eye drop therapies for the improvement of near vision

we saw a sequential improvement from 1Q's 56% to 2Q's 58%. Maybe if you could provide some more color on the key drivers of this improvement

if you can elaborate on the volume versus price drivers for key brands like Lipitor in developed markets in greater China